CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Trastuzumab +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02213289
NCT02213289Phase 2Completed
CompareCT.gov

PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma

University of Chicago·interventional·Posted Aug 11, 2014·Updated Apr 8, 2021

In Brief

A Phase 2 clinical trial evaluating Trastuzumab, ABT-806, and 4 other interventions for Adenocarcinoma. Completed, enrolled 80 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma
CountriesUnited States
CollaboratorsAbbVie

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 11, 2014
Enrollment StartJan 20, 2015
Primary CompletionFeb 1, 2020
Study CompletionAug 20, 2020
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 11.9 years ago

Interventions

Trastuzumabdrug

Trastuzumab

ABT-806drug

ABT-806

Bemarituzumabdrug

Bemarituzumab

Ramucirumabdrug

Ramucirumab

Nivolumabdrug

Nivolumab

Standard cytotherapydrug

FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)